XRTX — XORTX Therapeutics Balance Sheet
0.000.00%
- CA$7.46m
- CA$2.24m
Annual balance sheet for XORTX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | Interim Report | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.551 | 1.57 | 14.9 | 10.4 | 3.45 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.012 | 0.046 | 0.041 | 0.082 | 0.061 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.628 | 1.62 | 16 | 10.9 | 4.07 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | 0 | — | 0.093 | 0.024 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 0.838 | 1.8 | 17.4 | 12.4 | 5.47 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1 | 0.812 | 0.555 | 1.52 | 0.295 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1 | 0.812 | 4.19 | 5.38 | 0.826 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -0.163 | 0.987 | 13.2 | 7 | 4.64 |
Total Liabilities & Shareholders' Equity | 0.838 | 1.8 | 17.4 | 12.4 | 5.47 |
Total Common Shares Outstanding |